|
KR100927304B1
(ko)
*
|
2001-12-27 |
2009-11-18 |
다이이찌 세이야꾸 가부시기가이샤 |
β-아밀로이드 단백 생산·분비 저해제
|
|
GB0218041D0
(en)
*
|
2002-08-02 |
2002-09-11 |
Merck Sharp & Dohme |
Chemical process
|
|
GB0223039D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
GB0313772D0
(en)
*
|
2003-06-13 |
2003-07-23 |
Merck Sharp & Dohme |
Therapeutic treatment
|
|
PL379466A1
(pl)
|
2003-06-30 |
2006-09-18 |
Daiichi Sankyo Company , Limited |
Heterocykliczne pochodne metylosulfonu
|
|
AR045219A1
(es)
|
2003-08-08 |
2005-10-19 |
Pharmacopeia Inc |
Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
|
|
WO2005016876A2
(en)
|
2003-08-08 |
2005-02-24 |
Schering Corporation |
Cyclic amine bace-1 inhibitors having a benzamide substituent
|
|
GB0323258D0
(en)
|
2003-10-04 |
2003-11-05 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
AR047666A1
(es)
*
|
2004-02-20 |
2006-02-01 |
Merck Sharp & Dohme |
Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido
|
|
CA2574218A1
(en)
|
2004-07-22 |
2006-02-09 |
Schering Corporation |
Substituted amide beta secretase inhibitors
|
|
AU2006234441B2
(en)
|
2005-04-08 |
2011-07-07 |
Daiichi Sankyo Company, Limited |
Pyridylmethylsulfone derivative
|
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
|
WO2007092435A2
(en)
|
2006-02-07 |
2007-08-16 |
Wyeth |
11-beta hsd1 inhibitors
|
|
US9567396B2
(en)
|
2006-03-07 |
2017-02-14 |
Evonik Degussa Gmbh |
Notch inhibition in the prevention of vein graft failure
|
|
WO2007103114A2
(en)
|
2006-03-07 |
2007-09-13 |
The Brigham & Women's Hospital, Inc. |
Notch inhibition in the treatment or prevention of atherosclerosis
|
|
WO2011053822A2
(en)
|
2009-11-01 |
2011-05-05 |
The Brigham And Women's Hospital, Inc. |
Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
|
|
CA2676715A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
TW200920362A
(en)
|
2007-09-11 |
2009-05-16 |
Daiichi Sankyo Co Ltd |
Alkylsulfone derivatives
|
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
JP5377329B2
(ja)
*
|
2007-12-26 |
2013-12-25 |
Ｍｓｄ株式会社 |
スルホニル置換六員環誘導体
|
|
EP2291181B9
(en)
|
2008-04-18 |
2013-09-11 |
University College Dublin National University Of Ireland, Dublin |
Captodiamine for the treatment of depression symptoms
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
PE20121172A1
(es)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
Piperidinas sustituidas con actividad en la hdm2
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US9629891B2
(en)
|
2011-10-17 |
2017-04-25 |
Nationwide Children's Hospital, Inc. |
Products and methods for aortic abdominal aneurysm
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
|
RS56680B1
(sr)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme |
Kompozicije i postupci za lečenje kancera
|
|
KR102196882B1
(ko)
|
2012-12-20 |
2020-12-30 |
머크 샤프 앤드 돔 코포레이션 |
Hdm2 억제제로서의 치환된 이미다조피리딘
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
ES2704460T3
(es)
*
|
2014-01-06 |
2019-03-18 |
Bristol Myers Squibb Co |
Moduladores de ROR gamma de ciclohexilsulfona
|
|
US10441567B2
(en)
|
2014-01-17 |
2019-10-15 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
EP3706747B1
(en)
|
2017-11-08 |
2025-09-03 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US12485126B2
(en)
|
2018-07-19 |
2025-12-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US12552826B2
(en)
|
2018-08-07 |
2026-02-17 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US12173026B2
(en)
|
2018-08-07 |
2024-12-24 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
WO2020214834A1
(en)
|
2019-04-19 |
2020-10-22 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
BR112022012015A2
(pt)
|
2019-12-17 |
2022-08-30 |
Merck Sharp & Dohme Llc |
Inibidores de prmt5
|
|
US12595248B2
(en)
|
2019-12-17 |
2026-04-07 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US12441730B2
(en)
|
2019-12-17 |
2025-10-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
US20240116945A1
(en)
|
2022-09-02 |
2024-04-11 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
WO2024091437A1
(en)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
|
GEAP202516798A
(en)
|
2022-12-14 |
2025-10-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|